An interventional study of Low-dose iron (ferrous sulfate) and Yeast-bound iron (ferrous sulfate) in Iron Deficiency, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to female participants aged 16 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by University of Calgary · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing iron in Iron Deficiencies — 5 open to participants now, 7 under way, none of them phase 3. Iron · Iron Deficiencies.
Among the 21 studies testing iron in Iron Deficiencies, this one is the 18th largest by planned enrollment, is one of 5 that started in 2026, is one of 13 with no phase, and was the 16th registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →5 of the 21 studies testing iron in Iron Deficiencies are open now, in 3 countries. Recruiting first, the newest first:
Cajal Therapeutics Inc. · Sites in Australia
Ages 18–55 · Healthy volunteers
IBSA Farmaceutici Italia Srl · Sites in Italy
Ages 18–45 · Women only
Cairo University
Ages 12–16
Cairo University
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 16 Years to 35 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 111 across the 21 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 21 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 4 studies filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
4 of the studies testing iron in Iron Deficiencies that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07435766ETH ZurichIron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy | 2026-11 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT07613190Cairo UniversityAdjunctive Oral Iron Supplementation in Atopic Dermatitis | 2027-06 |
| NCT06427200Cairo UniversityEfficacy and Safety of Lactoferrin in Heart Failure Patients | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies testing iron in Iron Deficiencies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if different types and doses of oral iron supplements can improve iron levels, athletic performance, and gut health in young female athletes with low iron stores. The main questions it aims to answer are:
Researchers will compare three types of iron supplements:
This will help researchers find out which type of supplement is most effective and easiest on the stomach.
Participants will:
This clinical trial is designed to evaluate and compare the effects of three oral iron supplementation strategies on iron status, gut microbiota, and athletic performance in young female athletes with suboptimal iron levels. The study compares a low-dose iron supplement, a low-dose yeast-bound iron supplement (Lalmin® Fe10), and a high-dose iron supplement. The primary goal is to identify which iron supplement improves iron status most effectively while minimizing gastrointestinal symptoms and changes to the gut microbiota.
The rationale for the study is based on the high prevalence of iron deficiency among female athletes, especially those involved in endurance and high-intensity sports. Iron plays a key role in oxygen transport, energy production, and recovery, making it essential for optimal athletic performance. However, current supplementation practices often lead to poor compliance due to side effects and low absorption rates. The yeast-bound iron product being tested is hypothesized to improve absorption and tolerability by altering the site of absorption and reducing gastrointestinal distress.
Participants will be biologically female athletes aged 16-35 with suboptimal ferritin (≤50 µg/L), who are competitively trained and meet strict health and fitness criteria. After screening, eligible participants will be randomly assigned to one of three groups and consume their assigned supplement every other day for 12 weeks. Each supplement will be encapsulated to preserve blinding and consistency.
The study involves six in-person visits:
Visit 1 Screening and Consenting:
Study investigators will reach out electronically or by phone to individuals interested in participating in the study. At this time, participants will be informed about the study and eligibility will be confirmed. Iron status will be assessed using ferritin, achieved through a forearm venipuncture. Participants with suboptimal ferritin levels (≤50 µg/L) will be asked to complete a 3-day food record over the following week on non-consecutive days. This food intake data will be used to determine energy availability to ensure participants meet the minimum requirement of >30 kcal/kg lean body mass. Those who do not meet this requirement will be excluded from further participation.
Visit 2 Baseline Testing (Week 0):
Once inclusionary criteria has been confirmed and met, participants will undergo baseline measures of iron status through a forearm blood draw, they will complete a body composition assessment to assess lean body mass, and participants will complete a cycling-based aerobic fitness test (VO2 max) to characterize their fitness level. Participants will also be sent home with a package with SIMBA capsules, fecal sample collection kit, and collection instructions.
Visit 3 Baseline Testing (Week 0):
Participants will return 48-72 hours later to complete a cycling-based anaerobic fitness test (Wingate) and a countermovement jump test to assess fitness level. After fecal sample has been retrieved and picked up by study personal, participants will begin the 12-week nutritional intervention.
Nutritional Intervention:
Participants will consume an oral iron supplement every other day for 12 weeks. Participants will take their supplement within 30 minutes of morning training. If there is no morning training, participants will be instructed to consume immediately upon waking. The total dose of elemental iron is 40mg for the low dose group, 40mg for the yeast bound iron group, and 150mg for the high dose group, contained within a gelatin capsule. The iron-complexed yeast is a pasteurized (not live) Saccharomyces cerevisiae, a common nutritional yeast. There are no limits on how much can be consumed. They will also be reminded to take with food, a few hours before or after taking other medications or natural health products and avoid coffees, teas, dairy and dairy alternatives for two hours after consumption every other day. If they miss a dose, they will be recommended to take the next dose the next day and begin dosing every other day from there. After 4 and 8 weeks of consuming the supplement, participants will return to the lab for follow-up testing, consisting of a venipuncture blood draw (visits 4 and 5) and three-day food log (visit 4 only). At these visits they will be provided with another four-week supply of capsules. Participants will then be instructed to return to the lab to retrieve another 4 weeks of capsules, 8 weeks into the intervention, before completing their 12-week post-intervention tests. The Get Active Questionnaire (GAQ) and Menstrual Disorder of Teenagers (MDOT) will be completed at baseline; the Epworth Sleepiness Scale and Menstrual Bleeding Questionnaire will be completed monthly; the Gastrointestinal Symptoms Questionnaire, Post Exercise Short Recovery Scale, and Acute Recovery and Stress Scale will be assessed weekly through Qualtrics, an online survey platform.
Visit 4 Follow-Up (Week 4):
Participants will have a blood sample drawn for assessment of iron status and be instructed to complete a 3-day food log on three-non-consecutive days over the next week.
Visit 5 Follow-Up (Week 8):
Participants will have a blood sample drawn for assessment of iron to reduce the risk of iron overload.
Visit 6 Post Intervention (Week 12):
After the 12-week intervention has concluded, participants will return to the lab to repeat the aerobic exercise test (VO2).
Visit 7 Post Intervention (Week 12):
Participants will return to the lab to repeat measures done at baseline (blood status, body composition, anaerobic fitness test (Wingate and countermovement jump test), 3-day food log, fecal sample collection kit, and SIMBA capsule). At this time, participants will return any unused capsules to be counted for assessment of compliance.
Primary outcomes include changes in markers of iron status (ferritin, hemoglobin, RBC indices). Secondary outcomes include aerobic/anaerobic performance measures, body composition (DXA), substrate metabolism, gut microbiota composition (via fecal and intestinal sampling), and self-reported gastrointestinal symptoms. Safety and tolerability will be monitored at each study visit and through participant self-report.
Data will be analyzed using both traditional statistics (e.g., ANOVA) and machine learning methods for complex 'omics' data. Results will inform better supplementation strategies for female athletes and will be shared through academic publications.
The study will contribute to a greater understanding of iron supplementation strategies that are effective, tolerable, and beneficial to performance and health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Activity level based on Participant Classification Framework (McKay et al., 2022)
Exclusion Criteria:
Are pregnant or lactating or planning to become pregnant for the duration of the study. All participants must agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Additional exclusion criteria based on use of SIMBA capsules. Following is a summary of SIMBA capsules specific exclusion criteria:
Use of any medication in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g. opioids, prokinetics, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the study visit. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This supplement consists of encapsulated ferrous sulphate (40 mg elemental iron).
Dietary Supplement: Low-dose iron (ferrous sulfate)
Low dose iron (40 mg elemental iron) in the form of yeast-bound iron, specifically Lalmin® Fe10. This supplement consists of encapsulated ferrous sulphate complexed with inactivated Saccharomyces cerevisiae (nutritional yeast).
Dietary Supplement: Yeast-bound iron (ferrous sulfate)
This supplement consists of encapsulated ferrous sulphate (150 mg elemental iron).
Dietary Supplement: High-dose iron (ferrous sulfate)
Encapsulated low-dose ferrous sulphate (40mg elemental iron)
Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)
Encapsulated high-dose ferrous sulphate (150mg elemental iron)
Iron status blood markers
A forearm venous blood draw
Time frame: Baseline
Iron status blood markers
A forearm venous blood draw
Time frame: 4 weeks
Iron status blood markers
A forearm venous blood draw
Time frame: 8 weeks
Iron status blood markers
A forearm venous blood draw
Time frame: 12 weeks
Gut microbiota
Effects of the various iron formulations on the gut microbiota using the SIMBA capsule and stool sample analysis. Fecal Collection: Participants will provide two stool samples to assess fecal metabolites and gut microbiota composition. Participants will be provided a stool sample collection kit that will allow them to collect the sample in the privacy of their home. The kit will contain all necessary instructions and materials required to perform the collection. Gut microbiome Assessment: Participants will ingest a SIMBA capsule pre and post intervention. The capsule captures a small fluid sample from the small intestine, which will be retrieved upon excretion to examine the gut microbiome.
Time frame: Baseline
Gut microbiota
Effects of the various iron formulations on the gut microbiota using the SIMBA capsule and stool sample analysis. Fecal Collection: Participants will provide two stool samples to assess fecal metabolites and gut microbiota composition. Participants will be provided a stool sample collection kit that will allow them to collect the sample in the privacy of their home. The kit will contain all necessary instructions and materials required to perform the collection. Gut microbiome Assessment: Participants will ingest a SIMBA capsule pre and post intervention. The capsule captures a small fluid sample from the small intestine, which will be retrieved upon excretion to examine the gut microbiome.
Time frame: 12 weeks
VO2 Max
VO2 max testing on a cycling ergometer to assess peak power output, maximal oxygen consumption, and exercise thresholds. Individuals will begin with a 4-minute warm-up of low intensity, then proceed to a progressively increasing cycling challenge until they reach the point of voluntary exhaustion. Breath-by-breath measurement of gas exchange will be captured using open-circuit spirometry at rest, during exercise, and during recovery. Perceptual responses will be recorded during warm-up, every two minutes throughout exercise, and after task failure. Heart rate will be collected using a chest strap and measured throughout exercise. This method is used to evaluate the fitness levels of the participants. Metabolic cart measurements: Participants will wear a mask connected to a breath-by-breath metabolic cart to measure expired gases and minute ventilation. This equipment will continuously monitor the expired concentrations of O2 and CO2.
Time frame: Baseline
VO2 Max
VO2 max testing on a cycling ergometer to assess peak power output, maximal oxygen consumption, and exercise thresholds. Individuals will begin with a 4-minute warm-up of low intensity, then proceed to a progressively increasing cycling challenge until they reach the point of voluntary exhaustion. Breath-by-breath measurement of gas exchange will be captured using open-circuit spirometry at rest, during exercise, and during recovery. Perceptual responses will be recorded during warm-up, every two minutes throughout exercise, and after task failure. Heart rate will be collected using a chest strap and measured throughout exercise. This method is used to evaluate the fitness levels of the participants. Metabolic cart measurements: Participants will wear a mask connected to a breath-by-breath metabolic cart to measure expired gases and minute ventilation. This equipment will continuously monitor the expired concentrations of O2 and CO2.
Time frame: 12 weeks
Wingate
Wingate test completed on cycle ergometer to determine peak power output and fatigue index. During this test, participants will use a cycle ergometer. After a five-minute warm-up at low intensity, participants will pedal at maximum effort against a set resistance (7.5%) for 30 seconds, based on their body weight. Peak power will be assessed as well as other key performance metrics.
Time frame: Baseline
Wingate
Wingate test completed on cycle ergometer to determine peak power output and fatigue index. During this test, participants will use a cycle ergometer. After a five-minute warm-up at low intensity, participants will pedal at maximum effort against a set resistance (7.5%) for 30 seconds, based on their body weight. Peak power will be assessed as well as other key performance metrics.
Time frame: 12 weeks
Countermovement jump test
Researchers will use a force plate to assess low body and explosive strength. After a 10 minute warm-up where participants will perform 3 maximal CMJs, rest for two minutes, and perform a second set of 3 CMJs. Participants will complete 3-5 repetitions, with a minimum of 3, with 10-15 seconds between each jump, within a minimum of 10 seconds. Testing will occur before and after supplementation.
Time frame: Baseline
Countermovement jump test
Researchers will use a force plate to assess low body and explosive strength. After a 10 minute warm-up where participants will perform 3 maximal CMJs, rest for two minutes, and perform a second set of 3 CMJs. Participants will complete 3-5 repetitions, with a minimum of 3, with 10-15 seconds between each jump, within a minimum of 10 seconds. Testing will occur before and after supplementation.
Time frame: 12 weeks
Body composition
The DXA procedure uses a small amount of x-ray radiation to determine the amount of fat, bone, and muscle mass an individual has in his/her body.
Time frame: Baseline
Body composition
The DXA procedure uses a small amount of x-ray radiation to determine the amount of fat, bone, and muscle mass an individual has in his/her body.
Time frame: 12 weeks
Gastrointestinal Health
PROMIS and Gastrointestinal Symptom Questionnaire to assess gastrointestinal symptoms.
Time frame: Weekly from baseline to 12 weeks
Menstrual cycle
MDOT questionnaire to assess menstrual cycle.
Time frame: Baseline
Menstrual cycle
Menstrual Bleeding questionnaire to assess menstrual cycle.
Time frame: baseline
Menstrual cycle
Menstrual Bleeding questionnaire to assess menstrual cycle.
Time frame: 4 weeks
Menstrual cycle
Menstrual Bleeding questionnaire to assess menstrual cycle.
Time frame: 8 weeks
Menstrual cycle
Menstrual Bleeding questionnaire to assess menstrual cycle.
Time frame: 12 weeks
Short Stress and Recovery Scale (SSRS)
Short Stress and Recovery Scale (SSRS) to assess recovery and stress; higher scores under each domain indicate higher levels of stress or recovery, respectively
Time frame: Completed weekly from baseline to 12 weeks
Activity Readiness
Get Active Questionnaire to assess readiness for exercise.
Time frame: Baseline
Sleep
Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness
Time frame: Baseline
Sleep
Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness
Time frame: 4 weeks
Sleep
Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness
Time frame: 8 weeks
Sleep
Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness
Time frame: 12 weeks
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.
Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 6 months is below that.
Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iron · Ferrous sulfate